AstraZeneca, Merck Add Patent to Campaign on Lynparza Copies (1)

AstraZeneca Plc and partner Merck & Co. filed lawsuits adding a patent issued this week to battles over copies of the blockbuster cancer drug Lynparza proposed by four generic-drug makers.

Versions proposed by Natco Pharma Ltd., Sandoz Group AG, Cipla Ltd., and Zydus Lifesciences Ltd. infringe US Patent No. 12,144,810, which was issued Nov. 19 and covers an immediate-release composition of a solid form of olaparib, Lynparza’s active ingredient, according to four complaints filed Wednesday in the US District Court for the District of New Jersey. The patent—which hasn’t yet been listed in the US Food and Drug ...